MeiraGTx FY2025 license revenue rises to $75 million; net loss per share narrows to $1.42

MEIRAGTX HOLDINGS PLC -0.53% Pre

MEIRAGTX HOLDINGS PLC

MGTX

9.34

9.34

-0.53%

0.00% Pre
  • MeiraGTx published a press release reporting fourth-quarter and full-year 2025 financial and operational results and a corporate update.
  • Net loss attributable to ordinary shareholders was USD 114.2 million, or USD 1.42 per share, compared with a narrower loss in the prior year.
  • Total revenue was USD 81.39 million, including service revenue of USD 6.4 million (down 80.77%) and license revenue of USD 75.0 million.
  • Research and development expense was USD 129.62 million (up 8.45%), which MeiraGTx attributed mainly to higher manufacturing costs and increased activity across clinical and preclinical programs.
  • Cash, cash equivalents and restricted cash were USD 68.2 million at Dec. 31, 2025 (down 35.48%), and the company said it expects existing capital to fund operations into the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260800PRIMZONEFULLFEED9679097) on March 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.